Form 4: Madrigal Pharmaceuticals Director Paul Friedman Executes Stock Option and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4


Director Paul Friedman exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On April 8, 2024, Paul A. Friedman, a director of Madrigal Pharmaceuticals, exercised stock options to acquire 26,270 shares of common stock at a price of $9.45 per share.
  • Simultaneously, Friedman sold a total of 26,264 shares of common stock in multiple transactions at weighted average prices ranging from $242.9523 to $248.5907.
  • These sales were executed under a Rule 10b5-1 trading plan adopted on November 27, 2023.
  • Following these transactions, Friedman directly owns 185,735 shares of common stock and indirectly owns 655,540 shares through SQN LLC.
  • Friedman disclaims beneficial ownership of the shares held by SQN LLC except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects routine insider trading activity under a pre-arranged plan.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan suggests pre-planned and compliant trading activity.

Key Dates

DateDescription
11/27/2023Date the Reporting Person adopted a Rule 10b5-1 trading plan
04/08/2024Date of the earliest transaction: exercise of stock options and sale of common stock
04/10/2024Date of signature for the Form 4 filing
07/22/2026Expiration date of the stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.